Novel Drug Screening Platform: Tumor Organoid

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is known to be one of the most lethal cancers among all cancer types, with a relative 5-year survival rate of less than 8%. Currently, surgery is the only probable curative treatment for PDAC which is available for only 10-15% of the patients diagnosed with the cancer. Organoids resemble the original tissue in morphology and function with self-organizing capacity. Organoids can be cultured with high effectiveness from individual patient derived tumor tissue which makes them an extremely fitting model for translational uses and the improvement of personalized cancer medicine. Before personalized medicine based on organoids can be applied in the clinic, the improvement of drug screening platforms in terms of sensitivity and robustness is necessary.

Establishment and Advancement of Pancreatic Organoids

“…The field of preclinical research on PDAC using pancreatic and PDAC organoids has expanded considerably in recent years, particularly in the areas of PDAC organoid modeling, PDAC pathogenesis, microenvironments, drug screening, and drug response predictions for precision therapy [76,77].…”